GSK Patient Assistance Program Will Cover Newly Approved Tykerb
This article was originally published in The Pink Sheet Daily
Executive Summary
Tyrosine kinase inhibitor clears FDA March 13 for use in combination with Roche’s Xeloda for second-line treatment of advanced or metastatic HER2 positive breast cancer.